Long‐term outcomes of switching to aflibercept for treatment‐resistant neovascular age‐related macular degeneration. Issue 5 (11th February 2019)

• Record Type: Journal Article
• Authors: Spooner, Kimberly; Hong, Thomas; Nair, Rashmi; Chow, Nicholas Chian Chiang; Broadhead, Geoffrey K.; Wijeyakumar, Wijeyanthy; Chang, Andrew A.
• Is Part Of: Acta ophthalmologica. Volume 97:Issue 5(2019)
• Page Start: e706
• Page End: e712
• Publication Date: 2019-02-11
• Subjects: age‐related macular degeneration -- anti‐VEGF -- long‐term -- treatment resistance; Ophthalmology -- Periodicals; 617.7005
• DOI: 10.1111/aos.14046
• Languages: English
• ISSNs: 1755-375X

Abstract

Abstract: Purpose: To report 4‐year outcomes following the switch to aflibercept in treatment‐resistant neovascular age‐related macular degeneration (nAMD). Methods: In this prospective, open‐label, non‐controlled, clinical trial, 49 patients with treatment‐resistant nAMD received 2 mg intravitreal aflibercept as three loading doses every 4 weeks, followed by injections every 8 weeks for the first 48 weeks, then an individualized regimen for a further 36 months, following previous treatment with ranibizumab and/or bevacizumab. Outcome measures included best‐corrected visual acuity (BCVA), central retinal thickness (CRT), pigment epithelial detachment (PED) height and geographic atrophy (GA) surface area. Results: Of the 49 patients who were initially recruited, data from 39 eyes of 39 patients were available at 48‐month follow‐up. Mean age was 76.7 ± 7.2 years. Over the 48 months, these eyes received a mean of 32.1 ± 5.6 injections. The mean BCVA improved significantly following 12 months of treatment (4.9 ± 9.0 ETDRS letters, p < 0.001); however, this was not maintained and was similar to baseline after 48 months (mean difference −0.4 ± 13.3 letters between baseline and 48 months, p < 0.001). The reduction in CRT from baseline was 170.3 ± 143.3 μ m (p < 0.001) with absence of macular fluid in 56% of the 39 eyes at the end of month 48. PED height reduced by a mean 77.5 ± 20.0 μ m, and geographic atrophy increased by a mean of 4.1 ± 3.4 mm 2 (p < 0.01) over the 48 months. Conclusion: Aflibercept is an effective alternative therapy for treatment‐resistant nAMD. Good anatomical and stable functional responses are achievable with continued therapy. The lack of continued visual improvement may be representative of GA progression, reflecting the progression of late‐stage nAMD in these patients.